Consistent with this, Ji et al. reported that the expression of METTL3 was significantly lower in glioma tumor tissues than in adjacent normal tissues, and this downregulation mediated GBM occurrence by altering the PI3K/Akt pathway [53]. This evidence concerns the gene METTL3 and central nervous system cancer.